The adoption of prostate-specific antigen (PSA) test for screening symptomatic patients in the mid-1990s dramatically changed the profile of PCa patients, with trends towards detection of lower grade disease, including clinically insignificant tumours [3]. This evidence concerns the gene KLK3 and posterior cortical atrophy.